Theratechnologies Plans Open Sale Process Amid Buyout Interest

Theratechnologies has announced its decision to explore a potential sale of the company through an open and non-exclusive process, following interest from Future Pak, which has made a cash proposal of $3.51 to $4.50 per share. The Board of Directors has formed a special committee of independent directors to oversee this evaluation, engaging both Barclays and Fasken as advisors alongside Raymond James and Norton Rose Fulbright. While discussions with Future Pak are ongoing, Theratechnologies has cautioned that no transaction is guaranteed and reassured stakeholders that operations will continue as normal during this period. The company has opted not to provide further updates unless mandated by securities laws. This strategic move reflects the company's efforts to navigate its current financial challenges and improve its market position. Investors are advised to remain vigilant regarding the company's operational and financial developments.